Prof. Marx (Aachen, Germany)
- Boehringer Ingelheim
- HCP Portal
- Products
- Trajenta®
- Resources
- Prof. Marx (Aachen, Germany)
Prof. Marx (Aachen, Germany)
Published 27.05.2021 by Boehringer Ingelheim
An extensive dataset from a unique CVOT programme.
Transcript
Linagliptin is a DPP4 inhibitor with a unique and comprehensive CVOT programme here compared to the others because we had two CVOTs, we demonstrated CV safety but, in addition to that, and that is crucial in patients with T2D, the studies demonstrated kidney safety profile here and no increased risk in HHF.
